{"entity":{"id":"nct06824168","kind":"trial","name":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","aka":[],"tldr":"A phase 2 trial of Quizartinib in acute myeloid leukaemia, run by Daiichi Sankyo, now recruiting.","summary":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission is a phase 2 interventional study registered as NCT06824168 by Daiichi Sankyo, with 130 participants planned, started 2025-07-18 and due to reach its primary completion in 2028-06-06. Interventions recorded: Quizartinib High Dose and Quizartinib Low Dose.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06824168","url":"https://clinicaltrials.gov/study/NCT06824168"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["quizartinib"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06824168","phase":"2","setting":"A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission","sponsor":"Daiichi Sankyo","participation":[{"nct":"NCT06824168","source":"https://clinicaltrials.gov/study/NCT06824168","fetchedAt":"2026-10-07T16:55:06.589Z","studySha256":"425e3d616d0e806954bee8fb6a9d4c4097786b4f7148ad12e8b23c57b5531fea","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-16","leadSponsor":"Daiichi Sankyo","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":130,"enrolmentType":"ESTIMATED","siteCount":64,"recruitingSiteCount":50,"countries":["Australia","Brazil","China","South Korea","United States"]}],"started":"2025-07-18","startedType":"actual","enrolled":130,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06824168/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}